biostudies-literatureUnknownGebo KAHHS | NIH | National Institute of Allergy and Infectious Diseases Division of Intramural ResearchHHS | NIH | National Institute of Diabetes and Digestive and Kidney DiseasesHHS | NIH | National Institute on Drug AbuseU.S. Department of DefenseHHS | NIH | National Institute of Allergy and Infectious DiseasesHHS | NIH | National Center for Advancing Translational SciencesPost-COVID conditions (PCCs) are common and have significant morbidity. Risk factors for PCC include advancing age, female sex, obesity, and diabetes mellitus. Little is known about treatment, inflammation, and PCC. Among 882 individuals with confirmed SARS-CoV-2 infection participating in a randomized trial of COVID-19 convalescent plasma (CCP) vs control plasma with available biospecimens and symptom data, the association between early CCP treatment, cytokine levels, and PCC was evaluated. Cytokine and chemokine levels were assessed at baseline, day 14, and day 90 using a multiplexed sandwich immunoassay (Meso Scale Discovery). Presence of any self-reported PCC symptoms was assessed at day 90. Associations between CCP treatment, cytokine levels, and PCC were examined using multivariate lmBioe0061823https://www.ebi.ac.uk/biostudies/studies/S-EPMC10653913biostudies-literatureEarly antibody treatment, inflammation, and risk of post-COVID conditions.PMC10653913U24TR001609W911QY2090012R01AI120938S1F31DA054849R01AI152078R01DK131926Gebo KAHuaman MARuff JPatel BHabtehyimer FMcBee NAHanley DDas PBlair JELane KBaksh SSutcliffe CGHammitt LLShade DMosnaim GSPaxton JHCachay ERCurrier JSRam MCasadevall ACSSC-004 ConsortiumKlein SLKassaye SPekosz AGniadek TLevine AHeath SLBloch EMPatel EUTobian AARLaeyendecker OSullivan DJBaker ORGawad ALMeisenberg BAnjan SRaval JSFukuta YFernandez REShoham SForthal DNAbraham AGZhu XGerber JMfalseEarly antibody treatment, inflammation, and risk of post-COVID conditions.Post-COVID conditions (PCCs) are common and have significant morbidity. Risk factors for PCC include advancing age, female sex, obesity, and diabetes mellitus. Little is known about treatment, inflammation, and PCC. Among 882 individuals with confirmed SARS-CoV-2 infection participating in a randomized trial of COVID-19 convalescent plasma (CCP) vs control plasma with available biospecimens and symptom data, the association between early CCP treatment, cytokine levels, and PCC was evaluated. Cytokine and chemokine levels were assessed at baseline, day 14, and day 90 using a multiplexed sandwich immunoassay (Meso Scale Discovery). Presence of any self-reported PCC symptoms was assessed at day 90. Associations between CCP treatment, cytokine levels, and PCC were examined using multivariate l2023-01-01T00:00:00Z2023 Sep2025-04-19T16:15:46.782Z2024-11-21T03:37:43.67ZS-EPMC106539133772487010.1128/mbio.00618-23